Bio Techne Corp Stock Performance
| TECH Stock | USD 58.47 3.16 5.71% |
On a scale of 0 to 100, Bio Techne holds a performance score of 8. The firm shows a Beta (market volatility) of 1.92, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bio Techne will likely underperform. Please check Bio Techne's expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Bio Techne's price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Bio Techne Corp are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak fundamental indicators, Bio Techne demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 5.71 | Five Day Return 8.86 | Year To Date Return (18.20) | Ten Year Return 118.09 | All Time Return 53.4 K |
Forward Dividend Yield 0.0058 | Payout Ratio | Last Split Factor 4:1 | Forward Dividend Rate 0.32 | Dividend Date 2025-05-30 |
1 | Techne Reports Q3 Earnings What Key Metrics Have to Say | 05/07/2025 |
2 | Nigel Farage gets another huge boost for Reform UK in humiliation for Tories | 05/21/2025 |
| Bio Techne dividend paid on 30th of May 2025 | 05/30/2025 |
3 | Spotting Winners Bio-Techne And Research Tools Consumables Stocks In Q1 | 06/03/2025 |
4 | Disposition of 1280 shares by Herr Amy E. of Bio Techne at 44.33 subject to Rule 16b-3 | 06/09/2025 |
5 | Bio-Techne Corp Shares Acquired by Legacy Advisors LLC | 06/25/2025 |
6 | Bio-Technes New USP Deal on mAb and Gene Therapy May Boost Its Stock - Zacks Investment Research | 06/30/2025 |
7 | Assessing Bio-Techne Insights From 7 Financial Analysts | 07/09/2025 |
8 | Disposition of 32933 shares by Kim Kelderman of Bio Techne at 51.42 subject to Rule 16b-3 | 07/15/2025 |
9 | Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results | 07/17/2025 |
10 | Disposition of 48176 shares by Kim Kelderman of Bio Techne at 44.33 subject to Rule 16b-3 | 07/22/2025 |
| Begin Period Cash Flow | 180.6 M | |
| Total Cashflows From Investing Activities | -203 M |
Bio Techne Relative Risk vs. Return Landscape
If you would invest 5,017 in Bio Techne Corp on April 26, 2025 and sell it today you would earn a total of 830.00 from holding Bio Techne Corp or generate 16.54% return on investment over 90 days. Bio Techne Corp is currently generating 0.289% in daily expected returns and assumes 2.768% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Bio, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bio Techne Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bio Techne's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bio Techne Corp, and traders can use it to determine the average amount a Bio Techne's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1044
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TECH | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.77 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.29 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 8 92% of assets perform better |
Based on monthly moving average Bio Techne is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bio Techne by adding it to a well-diversified portfolio.
Bio Techne Fundamentals Growth
Bio Stock prices reflect investors' perceptions of the future prospects and financial health of Bio Techne, and Bio Techne fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio Stock performance.
| Return On Equity | 0.0653 | ||||
| Return On Asset | 0.0524 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 8.95 B | ||||
| Shares Outstanding | 156.77 M | ||||
| Price To Earning | 74.38 X | ||||
| Price To Book | 4.30 X | ||||
| Price To Sales | 7.58 X | ||||
| Revenue | 1.16 B | ||||
| Gross Profit | 801.67 M | ||||
| EBITDA | 310.37 M | ||||
| Net Income | 168.07 M | ||||
| Cash And Equivalents | 247.03 M | ||||
| Cash Per Share | 6.30 X | ||||
| Total Debt | 419.54 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.44 X | ||||
| Book Value Per Share | 12.87 X | ||||
| Cash Flow From Operations | 298.98 M | ||||
| Earnings Per Share | 0.83 X | ||||
| Market Capitalization | 9.17 B | ||||
| Total Asset | 2.7 B | ||||
| Retained Earnings | 1.33 B | ||||
| Working Capital | 458.04 M | ||||
| Current Asset | 253.89 M | ||||
| Current Liabilities | 54.15 M | ||||
About Bio Techne Performance
By evaluating Bio Techne's fundamental ratios, stakeholders can gain valuable insights into Bio Techne's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bio Techne has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bio Techne has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 151.65 | 85.43 | |
| Return On Tangible Assets | 0.12 | 0.16 | |
| Return On Capital Employed | 0.09 | 0.09 | |
| Return On Assets | 0.07 | 0.07 | |
| Return On Equity | 0.09 | 0.09 |
Things to note about Bio Techne Corp performance evaluation
Checking the ongoing alerts about Bio Techne for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bio Techne Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 99.0% of the company shares are owned by institutional investors | |
| On 30th of May 2025 Bio Techne paid $ 0.08 per share dividend to its current shareholders | |
| Latest headline from stockstory.org: Disposition of 48176 shares by Kim Kelderman of Bio Techne at 44.33 subject to Rule 16b-3 |
- Analyzing Bio Techne's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio Techne's stock is overvalued or undervalued compared to its peers.
- Examining Bio Techne's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bio Techne's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio Techne's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bio Techne's stock. These opinions can provide insight into Bio Techne's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bio Stock analysis
When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| CEOs Directory Screen CEOs from public companies around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |